Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A A Skvortsov

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Kardiologiia|March 15, 2017
[Soluble Suppression of Tumorogenicity 2 Increases Opportunities for Risk Stratification After Acute Heart Failure Decompensation]A A Skvortsov, V N Protasov, O Yu Narusov, et al.
Kardiologiia|December 29, 2023
The Effectiveness of Outpatient Treatment Under the Control of the Soluble ST2 Receptor Concentration in Patients With Heart Failure With Reduced Ejection Fraction After Acute Decompensation of Heart FailureM D Muksinova, O Yu Narusov, A V Sychev, et al.
Khirurgiia|March 16, 2016
[Surgical treatment of thoracoabdominal aortic aneurysms]Yu V Belov, E R Charchyan, A B Stepanenko, et al.
Kardiologiia|November 1, 2003
[Clinical, hemodynamic and neurohumoral effects of long-term therapy of patients with severe chronic heart failure with beta-adrenoblocker bisoprolol]Iu N Belenkov, A A Skvortsov, V Iu Mareev, et al.
Kardiologiia|January 10, 2019
A A Skvortsov, O Yu Narusov, M D Muksinova, et al.
Kardiologiia|February 22, 2018
[Head to Head Comparison of Suppression of Tumorogenicity 2 and Copeptin Significance for Prognosis of Patients After Acute Heart Failure Decompensation]O Y Narusov, D E Koshkina, V N Protasov, et al.
Terapevticheskii Arkhiv|November 3, 2006
[Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of Sadko-CHF study)]A A Skvortsov, V Iu Mareev, S N Nasonova, et al.
Kardiologiia|November 13, 2019
Head to Head Comparison of Suppression of Tumorogenicity 2 and Copeptin Significance for Prognosis of Patients After Acute Heart Failure DecompensationA A Skvortsov, Vladimir N Protasov, O Yu Narusov, et al.
Kardiologiia|August 3, 2006
[Effects of long term therapy with angiotensin converting enzyme inhibitor quinapril, antagonist of receptors to angiotensin II valsartan, and combination of quinapril and valsartan in patients with moderate chronic heart failure. Main results of the SADKO-CHF study]A A Skvortsov, S N Nasonova, A V Sychev, et al.
Kardiologiia|February 2, 2019
V N Protasov, O Yu Narusov, A A Skvortsov, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Kardiologiia|March 15, 2017
[Soluble Suppression of Tumorogenicity 2 Increases Opportunities for Risk Stratification After Acute Heart Failure Decompensation]A A Skvortsov, V N Protasov, O Yu Narusov, et al.
Kardiologiia|December 29, 2023
The Effectiveness of Outpatient Treatment Under the Control of the Soluble ST2 Receptor Concentration in Patients With Heart Failure With Reduced Ejection Fraction After Acute Decompensation of Heart FailureM D Muksinova, O Yu Narusov, A V Sychev, et al.
Khirurgiia|March 16, 2016
[Surgical treatment of thoracoabdominal aortic aneurysms]Yu V Belov, E R Charchyan, A B Stepanenko, et al.
Kardiologiia|November 1, 2003
[Clinical, hemodynamic and neurohumoral effects of long-term therapy of patients with severe chronic heart failure with beta-adrenoblocker bisoprolol]Iu N Belenkov, A A Skvortsov, V Iu Mareev, et al.
Kardiologiia|January 10, 2019
A A Skvortsov, O Yu Narusov, M D Muksinova, et al.
Kardiologiia|February 22, 2018
[Head to Head Comparison of Suppression of Tumorogenicity 2 and Copeptin Significance for Prognosis of Patients After Acute Heart Failure Decompensation]O Y Narusov, D E Koshkina, V N Protasov, et al.
Terapevticheskii Arkhiv|November 3, 2006
[Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of Sadko-CHF study)]A A Skvortsov, V Iu Mareev, S N Nasonova, et al.
Kardiologiia|November 13, 2019
Head to Head Comparison of Suppression of Tumorogenicity 2 and Copeptin Significance for Prognosis of Patients After Acute Heart Failure DecompensationA A Skvortsov, Vladimir N Protasov, O Yu Narusov, et al.
Kardiologiia|August 3, 2006
[Effects of long term therapy with angiotensin converting enzyme inhibitor quinapril, antagonist of receptors to angiotensin II valsartan, and combination of quinapril and valsartan in patients with moderate chronic heart failure. Main results of the SADKO-CHF study]A A Skvortsov, S N Nasonova, A V Sychev, et al.
Kardiologiia|February 2, 2019
V N Protasov, O Yu Narusov, A A Skvortsov, et al.
Pageof 5